Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
SERENA PIETERS
2 weeks
3 days
- The HIV virus cells, when inside the body, attack CD4 T Lymphocytes.
- The outer shell of the retrovirus consists of two glycoproteins, gp120 and gp41. These proteins are what allow the virus to latch to the lymphocytes, specifically to the CD4 receptor, and enter the cell. They hijack these cells and use them to rapidly produce more HIV cells until the cell dies and explodes.
- This explosion of genetic material causes what is being called “ Bystander Cell Death” or “Bystander Cell Infection”.
- The body is being infected by the virus and progressing towards AIDS, when the CD4 cell count falls below 200 cells/mm3.
Duration: Throughout entire treatment
- HIV attacks T-Cells using two types of glycoprotiens
- GP120 and GP 41
- Entry and Fusion Inhibitors
- Cyanovirin - N
- Maraviroc
Cyanovirin - N targets the GP120 to block the binding to the CD4 binding site
- Reduces HIV infection by over 90%
Blocks co-receptor sites on the GP120 HIV cell from binding to T-cell CCR5 co-receptors
As soon as a patient receives the HIV diagnosis, their skin sample should be taken and sent to the lab to begin the transitional process into CD34+ cell
Process Duration: 2 weeks
Virophage membranes are exposed to a series of electrical fields to make them more permeable. Genes specific to causing cell apoptosis are inserted into the virophage capsule.
Estimated Electroporation Process Duration:
3 days
Once these virophages are stable, they should immediately be inserted into the patient to fight infection.
Eventually, the virophages will have killed all infected cells and healthy cells will become protected from the virus with the inhibitors.
Like a cancer treatment, dosage will be based on a combination of patient comfort and T-cell count reaction
- The initial does will be based off of the patients T-cell count
- The virophages inserted should at minimum be equal to the T-cells present in the body but preferably two times that amount to account for the amount of HIV cells in the body
- From then, the dosage can be increased or decreased based on how the patient reacted to the treatment and how the T-cell levels change
Once the CD34+ cell is created, the cells are converted into T-cells.
These T-cells are exposed to inhibitors and inserted into the body
Process Duration: 3 weeks
The CD43+ cells are systematically exposed to developmental factors to convert the cell into a fully functioning T-cell that the body will recognize
Once these steps have been completed a precision and patient should discuss further amounts and intervals of infusion
1. Protecting Healthy Cells
- Entry and Fusion Inhibitors prevent the spread of infection
2. Fight HIV Infection
- Virophages attach to HIV cells and, once entered into a cell, kill the cell and prevent further infection
3. Prevent AIDS diagnosis
- Creating new T-cells allows for the immune system to remain functional and increase counts above 200 to avoid infection